reMYND’s ReS19-T program, managing calcium homeostasis for Alzheimer’s, has moved to MAD phase after demonstrating strong safety in SAD phase
21. Oktober 2021 07:00 ET
|
reMYND
Press release reMYND’s ReS19-T program, managing calcium homeostasis for Alzheimer’s, has moved to MAD phase after demonstrating strong safety in SAD phase Leuven Belgium, 21 October 2021: reMYND...